Gong LZ, Wang QW, Zhu JW. The combined detection of carcinoembryonic antigen, carcinogenic antigen 125, and carcinogenic antigen 19-9 in colorectal cancer patients. World J Gastrointest Surg 2024; 16(7): 2073-2079 [PMID: 39087124 DOI: 10.4240/wjgs.v16.i7.2073]
Corresponding Author of This Article
Jie-Wen Zhu, BMed, Associate Chief Technician, Department of Clinical Laboratory, Huangshi Central Hospital (Affiliated Hospital of Hubei Polytechnic University), Hubei Key Laboratory of Kidney Disease Pathogenesis and Intervention, Huangshi Tumor Molecular Diagnosis and Treatment Key Laboratory, Feiyun Street, Xisaishan District, Huangshi 435000, Hubei Province, China. 13647146857@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Jul 27, 2024; 16(7): 2073-2079 Published online Jul 27, 2024. doi: 10.4240/wjgs.v16.i7.2073
The combined detection of carcinoembryonic antigen, carcinogenic antigen 125, and carcinogenic antigen 19-9 in colorectal cancer patients
Ling-Zhen Gong, Qian-Wen Wang, Jie-Wen Zhu
Ling-Zhen Gong, Qian-Wen Wang, Jie-Wen Zhu, Department of Clinical Laboratory, Huangshi Central Hospital (Affiliated Hospital of Hubei Polytechnic University), Hubei Key Laboratory of Kidney Disease Pathogenesis and Intervention, Huangshi Tumor Molecular Diagnosis and Treatment Key Laboratory, Huangshi 435000, Hubei Province, China
Author contributions: Gong LZ, Wang QW, Zhu JW contributed equally to this work; Gong LZ, Wang QW designed the research study, performed the primary literature and data extraction, analyzed the data and wrote the manuscript; Gong LZ, Wang QW, Zhu JW were responsible for revising the manuscript for important intellectual content. All authors read and approved the final version.
Institutional review board statement: The study was reviewed and approved by Huangshi Central Hospital.
Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.
Conflict-of-interest statement: The authors declare no conflicts of interest for this article.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at 13647146857@163.com. Participants gave informed consent for data sharing.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jie-Wen Zhu, BMed, Associate Chief Technician, Department of Clinical Laboratory, Huangshi Central Hospital (Affiliated Hospital of Hubei Polytechnic University), Hubei Key Laboratory of Kidney Disease Pathogenesis and Intervention, Huangshi Tumor Molecular Diagnosis and Treatment Key Laboratory, Feiyun Street, Xisaishan District, Huangshi 435000, Hubei Province, China. 13647146857@163.com
Received: March 1, 2024 Revised: April 30, 2024 Accepted: May 22, 2024 Published online: July 27, 2024 Processing time: 143 Days and 4.6 Hours
Abstract
BACKGROUND
Hepatic metastases are common and difficult to treat after colorectal cancer (CRC) surgery. The predictive value of carcinoembryonic antigen (CEA), cancer antigen (CA) 125 and CA19-9 combined tests for liver metastasis is unclear.
AIM
To evaluate predictive value of combined tests for CEA, CA125, and CA19-9 levels in patients with liver metastases of CRC.
METHODS
The retrospective study included patients with CRC alone (50 cases) and patients with CRC combined with liver metastases (50 cases) who were hospitalized between January 2021 and January 2023. Serum CEA, CA125 and CA19-9 levels were compared between the two groups, and binary logistic regression was used to analyze the predictive value of the combination of these tumor markers in liver metastasis. In addition, we performed receiver operating characteristic (ROC) curve analysis to assess its diagnostic accuracy.
RESULTS
The results showed that the serum CEA, CA125 and CA19-9 levels in the CRC with liver metastasis group were significantly higher than those in the CRC alone group. Specifically, the average serum CEA level in the CRC with liver metastasis group was 162.03 ± 810.01 ng/mL, while that in the CRC alone group was 5.71 ± 9.76 ng/mL; the average serum CA125 levels were 43.47 ± 83.52 U/mL respectively. and 13.5 ± 19.68 U/mL; the average serum CA19-9 levels were 184.46 ± 473.13 U/mL and 26.55 ± 43.96 U/mL respectively. In addition, binary logistic regression analysis showed that CA125 was significant in predicting CRC liver metastasis (P < 0.05). ROC curve analysis results showed that the areas under the ROC curves of CEA, CA125 and CA19-9 were 0.607, 0.692 and 0.586.
CONCLUSION
These results suggest that combined detection of these tumor markers may help early detection and intervention of CRC liver metastasis, thereby improving patient prognosis.
Core Tip: In this study, combined detection of serum carcinoembryonic antigen, cancer antigen (CA) 125 and CA19-9 levels can improve the diagnostic accuracy and predictive value of patients with liver metastases after radical colorectal cancer (CRC) surgery. In particular, CA125 is significant in predicting liver metastasis. Receiver operating characteristic curve analysis showed that the combined detection of these markers has high diagnostic accuracy. Therefore, joint detection of these tumor markers can help early detection and intervention of CRC liver metastasis and improve patient prognosis.
